Performance of three diagnostic tests for tuberculosis

among Human Immunodeficiency Virus (HIV) patients

- **presenting to a health facility in an informal urban**
- **settlement in Nairobi, Kenya.**

Eunita A. Ochola1¶, Marshal M. Mweu2¶

 Department of Medical Laboratory Science, Faculty of Health Sciences, South Eastern

- Kenya University, Kitui, Kenya
- Department of Public and Global Health, Faculty of Health Sciences, University of Nairobi,

Nairobi, Kenya

*Corresponding author

- Email: eochola@seku.ac.ke
- 13 These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

 The absence of an accurate reference test complicates the evaluation of tuberculosis (TB) diagnostic tests among people living with Human Immunodeficiency Virus (PLWHIV). The objective of this study was to estimate (using Bayesian latent class models [BLCM]) the sensitivity (Se), specificity (Sp) and negative and positive predictive values (NPV and PPV) of sputum smear microscopy (SSM), Xpert Ultra and lipoarabinomannan antigen (LAM) tests for TB among PLWHIV in Nairobi, Kenya.

23 This cross-sectional study enrolled a total of 190 patients aged \geq 18 years with presumptive TB seeking treatment at the Kibra Community Health Center Comprehensive Care Centre (CCC) clinic between September 2022 and March 2023. The diagnostic data obtained from 26 the three tests were analysed using a BLCM framework to derive accuracy estimates of the three diagnostic tests.

28 The Xpert Ultra assay registered a higher Se (85.0; 95% PCI [41.4 – 99.4]) compared to 29 LAM (26.8; 95% PCI $\lceil 4.7 - 67.6 \rceil$) and SSM (56.7 $\lceil 16.4 - 97.4 \rceil$). However, SSM had the 30 highest Sp (99.6; 95% PCI [97.7 – 100.0]). The Xpert Ultra assay yielded the highest overall combination of Se and Sp at 80.8% (95% PCI [37.0 – 96.5]). On predictive values, SSM 32 recorded the highest PPV at 84.5% (95% PCI [38.4 – 99.4]). Nonetheless, all the tests exhibited noticeably high NPVs (>96%).

 An optimal testing approach in this low-prevalence TB setting could entail an initial screening with the more sensitive Xpert Ultra test, with any resultant positives retested with the more specific SSM test - a two-test serial testing strategy.

Introduction

 Worldwide, tuberculosis (TB) ranks among the main causes of mortality from a single pathogenic agent(1). Human Immunodeficiency Virus (HIV) infected patients have a 20 to 30 fold higher probability of contracting TB(2). As of 2017, approximately 9% of the 10 million new TB cases were people living with HIV (PLWHIV), with Africa accounting for a 72% disproportionate share(3). Kenya ranks amid the high-TB burden nations whose primary cause of death is TB(4). In Kenya, pulmonary TB is the most prevalent type and 66% of TB cases occur among those 48 aged \leq 44 years(5). In line with the national TB diagnosis and treatment guidelines, the

 commencement of TB treatment is informed by bacteriological confirmation of *Mycobacterium tuberculosis* (MTB). However, clinical diagnosis where bacteriological confirmation is not possible may suffice for initiation of treatment(6).

 Sputum smear microscopy (SSM) has been the main diagnostic tool for TB especially in developing countries (7). It is extensively used because it is easy to run, rapid, inexpensive and has high specificity (Sp) for TB diagnosis (8, 9). Nevertheless, it has a limited sensitivity (Se) of approximately 10,000 TB bacilli/ml of sputum. Notably, its poor Se poses a challenge for diagnosis of TB in PLWHIV since they have fewer bacilli in their sputum (10).

 Diagnostic tests with improved Se and rapid turnaround time among PLWHIV could lead to improved patient outcomes, reduced mortality and lower progressive transmission of TB (11). The real time polymerase chain reaction (PCR) assay utilizing the gene Xpert platform such as Xpert Ultra, offers better test Se and Sp with ability to discriminate between tuberculous and non-tuberculous mycobacteria(12). Moreover, the test may detect at least

 15.6 Colony forming units (CFU) of MTB/ml in sputum samples in under two hours(12). Nonetheless, the technical and operational cost implications of the diagnostic test in resource-limited settings remain a challenge(13, 14).

 With sputum production among HIV infected individuals being limited(15), the need for alternative biological specimens for the diagnosis of TB arises. A rapid immunochromatographic test detecting the *Mycobacterium* cell wall antigen lipoarabinomannan (LAM) in urine samples is available as a point-of-care test for TB (16). The test is easy to run, has no need for specialized equipment or laboratory facilities and results are obtainable within 25 minutes – rendering the test field applicable. Moreover, among PLWHIV, the test displays high Sp, with Se increasing with diminishing CD4 counts(15-18).

 Diagnostic studies evaluating the performance of SSM, Xpert Ultra and TB LAM among PLWHIV have previously been conducted globally (19, 20). A major shortcoming of these evaluations is that the index tests were evaluated against imperfect reference standards, thus 80 introducing bias in the accuracy estimates of the evaluated tests (21) . A superior alternative involves the use of latent class models fit using Bayesian methods that allow for concurrent evaluation of Se and Sp of two or more tests without prior knowledge of the unobserved disease status of individuals(22). Consequently, the objective here was to estimate the Se and Sp as well as the predictive values of SSM, Xpert Ultra and LAM tests for TB among HIV patients within an informal outpatient setting using a Bayesian latent class model (BLCM) framework.

Materials and Methods

Study setting, design and population.

 The study was carried out at the Kibra Community Health Centre; a level three state-run facility located in the southern part of Nairobi**.** Notably, the facility serves an immediate large informal-settlement population characterised by a high dual burden of HIV/AIDS and TB, which are leading causes of mortality in slums(23)**.** It registers around150-200 out-patients daily, conducts approximately 50-60 deliveries monthly and offers comprehensive care clinic (CCC) services to over 1,500 patients per month.

 A facility-based cross-sectional study was employed to evaluate the performance of the three diagnostic tests for TB. The rationale for the choice of this design stems not only from the descriptive nature of the study but also the ease of recruitment of study participants presenting to the CCC clinic for care.

Sample size and participant selection

 The required sample size was derived using the McNemar's sample size formula for paired proportions(24):

104
$$
n_{per \, test} = \left(\frac{Z_{\alpha/2}\sqrt{p_{disc} + Z_{\beta}\sqrt{p_{disc} - p_{diff}^2}}}{p_{diff}}\right)^2
$$

105
$$
p_{disc} = (1 - Se_1) + (1 - Se_2)
$$

106
$$
p_{diff} = (1 - Se_1) - (1 - Se_2)
$$

108 Where: $n_{\text{per test}} =$ sample size required for each test, $Z_{\frac{\alpha}{2}}(1.96)$ is the value required for the 109 two-sided 95% confidence level, and Z_{β} (-0.84) is the value specifying the desired power of 110 80%. Se_1 and Se_2 are estimates of Se of the Gene xpert MTB/RIF and SSM respectively from 111 literature i.e. Se_1 is 90.3% and Se_2 is 67.1% (25).

112 As per the above mentioned figures, a total sample size of 190 was generated, after an upward 113 adjustment by 5% to account for non-response.

 To obtain the required sample, individuals visiting the hospital's CCC clinic were systematically random sampled in their order of arrival where every seventh person (after an initial random start) who met the eligibility criteria was selected. Eligibility was limited to 117 PLWHIV (symptomatic or asymptomatic for TB) aged \geq 18 years who at the time of 118 recruitment (28th September 2022- 31st March 2023) were visiting the CCC at the facility for care and consented to participation in the study. Importantly, recruitment followed triage by the clinic nurse and examination by a physician.

¹²¹ **Ethical considerations**

 Written permission to conduct this study was obtained from and approved from the Kenyatta National Hospital -University of Nairobi Ethics and Research Committee (Ref. No. KNH/ERC/R/145 and KNH/ ERC/Mod & SAE/347), the Nairobi metropolitan Services (Ref. No. EOP/NMS/HS/222), as well as the National Commission for Technology and Innovation (NACOSTI) (Ref. No. NACOSTI/P/21/14098). Moreover, a written informed consent was secured from individual patients prior to enrolling them into the study.

Sample collection

 Participants were provided with clear instructions on collection of urine and sputum samples. Of note, the LAM and SSM tests were carried out immediately at the facility's laboratory by a trained laboratorian. Samples for the Xpert Ultra assay were stored in cooler boxes and delivered to a referral laboratory for processing. On enrolment, the participants' sociodemographic characteristics (age, sex, marital status, level of education, area of residence, occupation and highly active antiretroviral therapy status (HAART) were recorded.

Target condition

 The infection (latent) status being targeted by the three tests (Xpert Ultra, SSM and LAM) constitutes a respiratory or urine sample carrying either the live MTB, its DNA or cell wall 141 LAM antigen at any concentration.

Sputum Smear Microscopy (SSM)

 This was performed as per standard guidelines(7). Briefly, a sputum smear covering 2cm by 1 cm on the centre of the slide was prepared immediately after receipt of the sample. The smears were then stained with the primary stain 1% Carbol fuchsin for a period not exceeding 146 10 minutes. Decolourisation was then performed by flooding the slides with 25% sulphuric acid for 3 minutes and subsequently the counterstain 0.1% methylene blue was added for 1 minute. Slides were rinsed before every staining stage and excess water drained by gently tilting each slide. The slides were thereafter examined under a light microscope at 100x magnification. *Mycobacterium* quantification was achieved by counting the acid fast bacteria (AFB) as per the International Union Against TB and Lung Disease recommended grading

 of sputum smear microscopy(7). For analytical purposes, AFB counts above zero constituted a positive result; otherwise negative.

Gene Xpert Mycobacterium/ Rifampicin Ultra (Xpert Ultra)

 This was carried out as described elsewhere(26). Briefly, a sample reagent (a constitution of sodium hydroxide and Isopropanol) was added into a sputum sample in a ratio of 2:1 for liquefaction and inactivation of the sputum. The mixture was then vigorously shaken and incubated at room temperature for 15 minutes. The liquefied specimen was afterwards pipetted into the test cartridge (Cat. No. 42722, Cepheid). The pre-labelled test cartridge was loaded into the MTB/RIF test platform (Cepheid) where automated testing commenced. The semi-nested real time amplification and detection occurred in an integrated reaction tube and the results were printed. Results were interpreted as positive when MTB was detected.

Lateral Flow Urine Lipoarabinomannan (LAM)

164 Alere DetermineTM TB LAM antigen kit (Cat No. 238237, Abbott Diagnostics Scarborough) was used to test for the presence of TB LAM antigen in collected urine samples. This was 166 executed as per the instructions in the Alere DetermineTM TB LAM antigen manual (27). A total of 60ul of urine was added into the strip sample well. In order to allow for the urine to flow towards both the test and control windows, the strip was incubated at room temperature for 25 minutes. A positive result was denoted by the appearance of two colour bands; one band on the control line being indicative of a negative result.

Statistical analysis

 A Bayesian latent class model fitted in OpenBUGS v3.2.2(28) but called from R software through the 'BRugs' package(29) was used to estimate the TB prevalence, Se and Sp of the three tests together with their predictive values. The guidelines for standards for reporting

175 diagnostic accuracy studies that use BLCMs were used to inform the analysis and reporting 176 of the results (30) . The model code is available as underlying data (31) .

177

178 Three assumptions are necessary when fitting a $BLCM(32)$. Firstly, the tests should be conditionally independent given the TB infection status. This was met since microscopy targets the live bacterium, Xpert Ultra amplifies and detects the *Mycobacterium* DNA and TB LAM detects the *Mycobacterium* cell wall LAM antigen. Hence, the probability of testing either positive or negative on one diagnostic tool did not depend on the outcome of the other tests. Secondly, the Se and Sp of the tests being evaluated should be constant across the subpopulations studied. With a single target population, as was the case here, the tests' constancy premise was likely to be upheld. Thirdly, the target population should consist of two or more subpopulations with different prevalences. In situations where only a single population exists, at least three tests are necessary to provide sufficient degrees of freedom to achieve model identifiability (30)

189

190 A multinomial distribution was assumed for the counts (0) of the different test combinations 191 (e. g. $+$, $+$, $+$) and took the form below:

192 $O \mid Se_i Sp_i P \sim multinomial (Prob, n)$

193 Where Se_i and Sp_i reflect the specific test characteristics of the individual tests ($i = 1, 2, 3$), 194 P denotes the prevalence for the singular population, **Prob** is a vector of probabilities of 195 observing different test combinations and n denotes the sample size of the study population. 196 As an illustration, the probability of an individual testing positive on all three tests is given 197 by:

199
$$
Prob = Pr\left(T_1^+ T_2^+ T_3^+ | D^+\right) + Pr\left(T_1^+ T_2^+ T_3^+\middle| D^-\right)
$$

$$
= Se_1 Se_2 Se_3P + [1 - Sp_1][1 - Sp_2][1 - Sp_3][1 - P]
$$

 With three tests, a total of seven degrees of freedom was sufficient to estimate the required seven parameters (the Se and Sp of the three tests together with the single population prevalence). Since there was no reliable prior information for any of the tests, uninformative 204 priors (*beta* $(1, 1)$) were used as initial parameters for the model.

205 The positive predictive value (PPV) and negative predictive value (NPV) of the test (*i*) were 206 estimated as follows:

207
$$
ppv_i = PSe_i/(PSe_i + [1 - P][1 - Sp_i])
$$

208
$$
npv_i = [1 - P]Sp_i/(P[1 - Se_i] + [1 - P]Sp_i
$$

209 Two Markov Chain Monte Carlo chains each having different values were used to initialise 210 the Bayesian model. Convergence of the chains was then evaluated via the time series plots of 211 selected variables and the Gelman-Rubin diagnostic plots. The posterior distributions of the 212 test estimates (Se, Sp and the predictive values) and the population prevalence were reported 213 as the median and the associated 95% posterior credible intervals (PCI). The Youden index 214 which is a measure of a test's overall diagnostic ability was also computed as : $Se + Sp - 1$ 215 (33).

²¹⁶ **Results**

217 Of the 190 participants, two were unable to provide all the required samples and were thus 218 excluded from the analysis. Another five were excluded on the basis of their Xpert Ultra 219 results being invalid.

220 The sociodemographic characteristics and information on HAART status is as shown in 221 Table 1. The median age of the participants was 43 years (Range: $19 - 82$ yrs). The majority 222 of participants were female $(64.0\%, n=117)$, married $(60.7\%, n=111)$, with only 2.2% $(n=4)$

- 223 lacking a formal education. A substantial percentage of the participants was on HAART
- 224 (97.5%, n=178).

225

- 226 **Table 1: Summary statistics on the sociodemographic characteristics and information**
- 227 **on HAART status for HIV patients presenting to a primary health facility in an**
- 228 **informal settlement, Nairobi County, Kenya. (n=183)**

229 HAART; Highly Active Antiretroviral Therapy

231 The cross-tabulated counts of the tests' outcomes are displayed in Table 2.

- 232 **Table 2: Cross- classified results for LAM, Xpert Ultra and SSM tests for diagnosis of**
- 233 **TB among PLWHIV presenting to the Kibra Community Health Centre CCC clinic,**
- 234 **Nairobi County, Kenya. (n=183)**

236

237 The estimates of the Se and Sp of the three tests, along with their respective predictive values 238 and the prevalence of MTB infection are shown in Table 3. The Xpert Ultra assay registered 239 a higher Se (85.0; 95% PCI [41.4 – 99.4]) compared to LAM (26.8; 95% PCI [4.7 – 67.6]) 240 and SSM (56.7 [16.4 – 97.4]). However, SSM displayed the highest Sp (99.6; 95% PCI [97.7] $241 - 100.0$]). As per the Youden indices, Xpert Ultra yielded the highest overall combination of 242 Se and Sp at 80.8% (95% PCI [37.0 – 96.5]). On predictive values, SSM recorded the highest 243 PPV at 84.5% (95% PCI [38.4 – 99.4]). Nonetheless, all the tests exhibited noticeably high 244 NPVs (>96%). The true prevalence of MTB infection in this HIV-infected outpatient 245 population was 4.1% (95% PCI $\lceil 1.2 - 11.2 \rceil$).

247 **Table 3. Estimates of prevalence, sensitivity, and specificity of LAM, Gene Xpert** 248 **Ultra, and SSM tests for MTB infection among HIV patients as well as their** 249 **corresponding predictive values and Youden indices**.

251 Se; Sensitivity, Sp; Specificity, PCI; Posterior confidence interval, LAM; Lipoaribomannan, P;

252 Prevalence, NPV; Negative predictive value, PPV; Positive predictive values

Discussion

 This study has utilized Bayesian latent class analysis for the estimation of the accuracy of SSM, Xpert Ultra and LAM tests (together with their corresponding predictive values) for the diagnosis of TB infection among PLWHIV. This is a key strength in this study since BLCM allows for the estimation of index tests' characteristics devoid of classification errors typically inherent in traditional evaluation studies employing the use of imperfect reference standards(21). Accordingly, the estimates obtained from this study can be considered generalisable to settings with similar MTB burden among PLWHIV.

 On Se, Xpert Ultra assay recorded the highest Se of the three tests. This result is in agreement 265 with previous reports that demonstrated the superiority of Xpert Ultra Se over other tests in TB screening and diagnosis among PLWHIV in outpatient settings. In particular, in a systematic review involving studies conducted in high TB prevalence settings among PLWHIV, the Xpert Ultra test Se ranged between 81% - 90%(20). The superiority of the test's Se owes to its low detection limit of tubercle bacilli (16 CFU/ ml of sputum)(34) 270 compared to SSM whose threshold is 5,000 - 10,000 CFU/ ml of sputum (35) and LAM at \sim 2000 CFU / ml (36, 37).

 The LAM test exhibited the lowest Se in the diagnosis of TB in the present study. This performance is comparable with findings from studies carried out in other outpatient settings. For instance, among existing, ART-naïve and newly diagnosed HIV patients presenting to 275 outpatient facilities in LMICs, LAM's Se was found to range between 25% - 30% (17, 36, 38, 39). Notably, an inverse relationship has been demonstrated, with LAM's test Se increasing with reducing CD4 counts among critically ill HIV patients(17, 40). LAM Se was observed

278 to be at its highest ($\geq 65\%$) among patients with CD4 counts <50 cells/ul and Se of 35%-55% for patients with CD4 counts between100 and 200 cells/ul respectively (17, 40). Increased uptake of ARV therapy in the present study setting may have contributed to improved CD4 counts in the patient population resulting in a low Se of the LAM test - underscoring its limited utility in this setting. SSM registered a test Se of 56.7% which falls within the 18% - 94.2% range observed in other studies(41, 42). The wide variability in performance is attributable to the number of CFUs available in a sample, with Se increasing with higher CFUs. Moreover, the test Se is also highly dependent on user expertise and other technical and operational factors (42).

 As regards Sp, SSM exhibited the highest which is consistent with findings from studies carried out in outpatient settings among PLWHIV(43, 44). The Sp displayed by LAM is also corroborated by findings from other studies carried out in similar low-resource settings where specificities ranging between >90%-100% were registered (36, 38, 45, 46). Xpert Ultra Sp is in agreement with specificities found in other similar settings where the test Sp was reported to range between 78%- 96% (20, 47).

 False negative and false positive results compromise Se and Sp estimates respectively. As for LAM and SSM, false negative results are more likely to occur in patients with bacterial load below the tests detection limits(48). Additionally, LAM is more likely to give false negative results in patients who have already received anti-TB treatment(49). False positive results by LAM have been demonstrated in samples contaminated with non-Mycobacterial pathogens such as *Nocardia* and *Candida* spp. that similarly exhibit LAM-like glycoprotein antigen(46). SSM is also unable to distinguish MTB from other smear-positive *Mycobacteria* spp.(50). False positives by Xpert Ultra could be attributable to detection of MTB DNA in patients recently cured of TB (44).

 Notably, in this population, the three tests' sensitivities displayed wide credible intervals (signifying low precision of the estimates) since there were few diseased individuals. In contrast, the tests' Sps demonstrated high precision owing to the significant number of truly non-diseased individuals. Overall, in this low-prevalence TB setting, Xpert Ultra affords good promise for informing treatment and surveillance for TB among PLWHIV.

 With low MTB prevalence (4.1%), generally low PPVs but high NPVs would be anticipated for the three tests. These estimates signify a stronger confidence in a negative than a positive test result. Consequently, in this low-prevalence setting where the probability of false positives is highly contemplated, a multiple testing strategy with serial interpretation of the test results may be necessary in order to raise the confidence in a positive test result. This could entail an initial screening with the more sensitive Xpert Ultra test, with any resulting positives followed up with the more specific SSM test. This approach should assure that false positive individuals are not unnecessarily subjected to protracted therapy for TB.

Conclusions

 The Xpert Ultra assay registered the highest Se compared to SSM and LAM. However, SSM registered the highest Sp and thus PPV estimate. Nevertheless, the three tests recorded similar NPVs. Owing to the low prevalence of TB in the study setting, an optimal testing approach could entail an initial screening with the more sensitive Xpert Ultra assay, with any resultant positives re-tested with the more specific SSM test – a serial testing strategy - to bolster the overall PPV of a TB testing and surveillance programme.

³²⁵ **Acknowledgments**

- 326 The authors sincerely thank the study participants, the administration and staff at Kibra
- 327 Community Health Centre for making it possible to realise this research work.

References

 1. WHO. World Health Organization annual report 2019 WHO Country Office Lebanon: health for all. Cairo: World Health Organization. Regional Office for the Eastern Mediterranean, 2020 2020-06. Report No.: 9789290223207.

 2. WHO. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization. Geneva: 2017.

 3. World Health O. Global tuberculosis report 2018. Geneva: World Health Organization, 2018 2018. Report No.: 9789241565646.

 4. Enos M, Sitienei J, Ong'ang'o J, Mungai B, Kamene M, Wambugu J, et al. Kenya tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in Kenya. PLoS One. 2018;13(12):e0209098. doi: 10.1371/journal.pone.0209098. PubMed PMID: 30586448; PubMed Central PMCID: PMCPMC6306266.

 5. MOH. Kenya Tuberculosis Prevalence Survey: Final Survey Report. Nairobi, Kenya: 2016.

 6. MOH. Guidelines for management of Tuberculosis and Leprosy in Kenya. Nairobi, Kenya: 2013.

 8. Akanbi MO, Achenbach C, Taiwo B, Idoko J, Ani A, Isa Y, et al. Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study. BMC Pulm Med. 2017;17(1):87. doi: 10.1186/s12890-017-0430-6. PubMed PMID: 28558662; PubMed Central PMCID: PMCPMC5450144.

 9. Gelaw B, Shiferaw Y, Alemayehu M, Bashaw AA. Comparison of loop-mediated isothermal amplification assay and smear microscopy with culture for the diagnostic accuracy of tuberculosis. BMC Infect Dis. 2017;17(1):79. doi: 10.1186/s12879-016-2140-8. PubMed PMID: 28095790; PubMed Central PMCID: PMCPMC5240421.

 10. Behr MA, Warren SA, Salamon H, Hopewell PC, de Leon AP, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. The Lancet. 1999;353(9151):444-9. doi: 10.1016/s0140-6736(98)03406-0.

 11. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014(1):CD009593. doi: 10.1002/14651858.CD009593.pub3. PubMed PMID: 24448973; PubMed Central PMCID: PMCPMC4470349.

 12. Chakravorty S SA, Rowneki, M PH, Cao Y, Ryan J, Banada PP,, Deshpande S SS, Gall A, Glass J,, Krieswirth B SS, Nabeta P,, Tukvadze N RC, Skrahina A, Tagliani E,, Cirillo DM

 14. Stephen D. Lawn, Sophie V. Brooks, Kranzer K, MPN, Andrew Whitelaw, Monica Vogt, et al. Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study. PLOS MEDICINE. 2011;8. doi: 10.1371/journal.pmed.1001067.

 15. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med. 2010;16(3):262-70. doi: 10.1097/MCP.0b013e328337f23a. PubMed PMID: 20375787; PubMed Central PMCID: PMCPMC5454484.

 16. Huerga H, Ferlazzo G, Bevilacqua P, Kirubi B, Ardizzoni E, Wanjala S, et al. Incremental Yield of Including Determine-TB LAM Assay in Diagnostic Algorithms for Hospitalized and Ambulatory HIV-Positive Patients in Kenya. PLoS One. 2017;12(1):e0170976. doi: 10.1371/journal.pone.0170976. PubMed PMID: 28125693; PubMed Central PMCID: PMCPMC5268475.

 17. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC infectious diseases. 2014;14:110. Epub 2014/02/28. doi: 10.1186/1471-2334-14-110. PubMed PMID: 24571362; PubMed Central PMCID: PMCPmc3944827.

 18. Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database Syst Rev. 2016(5):CD011420. doi: 10.1002/14651858.CD011420.pub2. PubMed PMID: 27163343; PubMed Central PMCID: PMCPMC4916932.

 19. Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M, et al. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis. 2009;9:53. doi: 10.1186/1471- 2334-9-53. PubMed PMID: 19419537; PubMed Central PMCID: PMCPMC2690598.

 20. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. The Cochrane database of systematic reviews. 2021;2:CD009593. doi: 10.1002/14651858.CD009593.pub5. PubMed PMID: 33616229.

 21. Claes Enøe, Marios P Georgiadis, Johnson WO. Estimation of sensitivity and specificity of diagnostic tests and disease prevalence when the true disease state is unknown, Preventive Veterinary Medicine. 2000;45(1–2):61-81.

PubMed PMID: 19864480; PubMed Central PMCID: PMC2812290.

Page **24** of **30**

 35. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353(9151):444-9. doi: 10.1016/s0140-6736(98)03406-0. PubMed PMID: 9989714.

 36. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV- infected adults. Journal of acquired immune deficiency syndromes. 2014;66(3):270-9. doi: 10.1097/QAI.0000000000000151. PubMed PMID: 24675585; PubMed Central PMCID: PMC4146703.

 37. Kawasaki M, Echiverri C, Raymond L, Cadena E, Reside E, Gler MT, et al. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. PLoS Med. 2019;16(4):e1002780. doi: 10.1371/journal.pmed.1002780. PubMed PMID: 30978194; PubMed Central PMCID: PMC6461223 following competing interests: MK, TO, RI, RH and KK are employees of Otsuka Pharmaceutical Co., Ltd. YL is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc., which is a subsidiary of Otsuka Pharmaceutical Co., Ltd. During the conduct of the clinical studies, MTG was an employee of Otsuka (Philippines) Pharmaceutical Inc., which is a subsidiary of Otsuka Pharmaceutical Co., Ltd. The rest of the authors declare no conflicts of interest associated with this manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

 38. Balcha TTW, N. Sturegard, E. Skogmar, S. Reepalu, A., Jemal ZH, Tibesso G, Schon T, Bjorkman P. Detection of lipoarabinomannan in urine for identification of active

 40. Aliasgar Esmail a, b Anil Pooran,a,b Natasha F. Sabur,a,c Mohammed Fadul,a,b Mantaj S. Brar,d Suzette Oelofse,a,b, Michele Tomasicchio a, b Keertan Dhedaa,b,e,f. An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag. Journal of clinical microbiology. 2020. doi: 10.1128/JCM.

 41. Jean Claude Semuto Ngabonziza WS, Florence Mutua, Gabriela Torrea, Augustin Dushime,, Michel Gasana EA, Schifra Uwamungu, Alaine Umubyeyi Nyaruhirira, Dufton Mwaengo and, Muvunyi CM. Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda. BMC infectious diseases. 2016. doi: 10.1186/s12879-016-2009-x.

 42. Mecky Matee LM, Tarja Lounasvaara, Wendy Wieland-Alter,, Richard Waddell JL, Muhammad Bakari,, Reyn KPaCFv. Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. 2008. doi: 10.1186/1471-2458-8-68.

 44. Balcells ME, García P, Chanqueo L, Bahamondes L, Lasso M, Gallardo AM, et al. Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2012;16(10):1349-53. Epub 2012/08/07. doi: 10.5588/ijtld.12.0156. PubMed PMID: 22863872.

 45. Paul K. Drain M, MPH1,2, Elena Losina, PhD1,3,4, Sharon M. Coleman, MS6, Janet Giddy, MBBCh7, Douglas Ross, MBBCh, MBA8, Jeffrey N. Katz, MD4, and Ingrid V. Bassett, MD, MPH. Value of Urine Lipoarabinomannan Grade and Second Test for Optimizing Clinic-based Screening for HIV-associated Pulmonary Tuberculosis. 2015.

 46. Peter J, Theron G, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC infectious diseases. 2015;15:262. doi: 10.1186/s12879-015-0967-z. PubMed PMID: 26156025; PubMed Central PMCID: PMC4495934.

⁵⁷³ **Supporting information**

- 574 **S1 File**. **Harvard Dataverse: Replication Data for: Performance of three diagnostic tests**
- 575 **for tuberculosis among HIV patients presenting to a primary care facility in an informal**
- 576 **settlement in Nairobi County, Kenya**. [https://doi.org/10.](https://doi.org/10.7910/DVN/PYRPCQ)⁷⁹¹⁰/DVN/PYRPCQ(31)